0001592052-13-000001.txt : 20131122 0001592052-13-000001.hdr.sgml : 20131122 20131122134401 ACCESSION NUMBER: 0001592052-13-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20131122 DATE AS OF CHANGE: 20131122 EFFECTIVENESS DATE: 20131122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Centrexion Corp CENTRAL INDEX KEY: 0001592052 IRS NUMBER: 320402377 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-206864 FILM NUMBER: 131237686 BUSINESS ADDRESS: STREET 1: 509 S. EXETER ST., SUITE 202 CITY: BALTIMORE STATE: MD ZIP: 21202 BUSINESS PHONE: 212-956-1111 MAIL ADDRESS: STREET 1: 509 S. EXETER ST., SUITE 202 CITY: BALTIMORE STATE: MD ZIP: 21202 D 1 primary_doc.xml X0707 D LIVE 0001592052 Centrexion Corp 509 S. EXETER ST., SUITE 202 BALTIMORE MD MARYLAND 21202 410-522-8701 DELAWARE None None Corporation true 2013 Sol Barer c/o Centrexion Corporation 509 S. Exeter St., Suite 202 Baltimore MD MARYLAND 21202 Director Isaac Blech c/o Centrexion Corporation 509 S. Exeter St., Suite 202 Baltimore MD MARYLAND 21202 Director Kerrie L. Brady c/o Centrexion Corporation 509 S. Exeter St., Suite 202 Baltimore MD MARYLAND 21202 Executive Officer James N. Campbell c/o Centrexion Corporation 509 S. Exeter St., Suite 202 Baltimore MD MARYLAND 21202 Executive Officer Director Jeffrey B. Kindler c/o Centrexion Corporation 509 S. Exeter St., Suite 202 Baltimore MD MARYLAND 21202 Executive Officer Arnold L. Oronsky c/o Centrexion Corporation 509 S. Exeter St., Suite 202 Baltimore MD MARYLAND 21202 Director Biotechnology Decline to Disclose 06b false 2013-11-20 false true true Series B Convertible Preferred Stock true (1) 1,996,980 shares issued in connection with a merger; (2) 418,950 shares issued in connection with the conversion of existing bridge notes of Issuer; and (3) 142,857 shares issued as payment for consulting services. 0 N/A None Maxim Group LLC 120708 405 Lexington Avenue New York NY NEW YORK 10174 All States false 35000000 14728886 20271114 false 98 1178311 0 Maxim will also receive warrants to purchase 673,321 shares of Series B Convertible Preferred Stock of Centrexion Corporation, par value $0.001 per share as part of its fee for its placement agent services. 416388 true To pay back salary for executive officers: (1) Kerrie Brady, (2) James Campbell and (3) Jeremy Kindler. false Centrexion Corp /s/ Sol Barer Sol Barer Chairman and President 2013-11-22